ALSO NOTED: FDA outlines tazarotene data demands; Elan repays $240M; FDA OKs BioMarin's Naglazyme; and much more...

> Irvine, California-based Allergan says that the FDA has outlined how it can improve oral tazarotene's risk-benefit profile. Allergan says it believes it can mount a pivotal trial to satisfy the agency's demands for new data. Release

> Despite problems with Tysabri, Ireland's Elan says it will retire more than $240 million in debt due in 2008. Release

> The FDA has approved BioMarin's Naglazyme for Maroteaux-Lamy syndrome, a rare disease in which a buildup of carbohydrates triggers a dysfunction of tissue and organs. Story

> The FDA has approved an expanded indication for Enbrel to physical function in patients with psoriatic arthritis. Release

> Bayer Greater China plans to rapidly expand its business in China with plans to invest $1.8 billion over six years. Story

> TransMolecular of Birmingham, Alabama, has begun a Phase II trial of 131I-TM-601 in adult patients with recurrent high-grade glioma. Release

> The board of India's Matrix Laboratories has approved a merger with Strides Arcolab. Release

> Codexis of Redwood City, California, has received its first milestone payment from Pfizer. Release

And Finally... Forbes examines the promising work of Canada's Vasogen in developing Celacade for fighting cardiac inflammation. Article

Suggested Articles

Pfizer licensed the drugs, gamma secretase inhibitor nirogacestat and MEK inhibitor mirdametinib, to SpringWorks in 2017.

The company, which was co-founded by Jim Mellon, has reeled in $165 million in 18 months to establish itself at the forefront of the longevity field.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.